Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorth Atl.smlr Regulatory News (NAS)

Share Price Information for North Atl.smlr (NAS)

Share Price is delayed by 15 minutes
Get Live Data
390.00    0.00 (0.00%)
Bid:
385.00
Ask:
392.00
Spread: 7.00 (1.818%)
Market Cap: £498.18m
NAS Live PriceLast checked at - London Stock Exchange

Intraday North Atl.smlr Share Chart

Interim Management Statement

18 Jun 2013 15:01

RNS Number : 3195H
North Atlantic Smlr Co Inv Tst PLC
18 June 2013
Β 

ο»Ώ

NORTH ATLANTIC SMALLER COMPANIES INVESTMENT TRUST PLC

Β 

INTERIM MANAGEMENT STATEMENT FOR THE PERIOD ENDED 31 MAY 2013

Β 

To the members of North Atlantic Smaller Companies Investment Trust PLC

This interim management statement has been produced solely to provide additional information to shareholders as a body in accordance with the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules. It should not be relied upon by any other party or for any other purpose.

Β 

This interim management statement relates to the period from 1 February 2013 to 31 May 2013, and contains information that covers this period, and up to the date of publication of this interim management statement, unless otherwise specified.

Β 

Investment Objective

The objective of North Atlantic Smaller Companies Investment Trust PLC ("the Company") is to provide capital appreciation through investment in a portfolio of smaller companies principally based in countries bordering the North Atlantic Ocean.

Β 

Financial Highlights

Cumulative performance

As at

31 May 2013

3 months %

6 months %

1 year %

3 years %

5 years %

Diluted NAV*

1,749p

1.6

8.7

22.7

43.5

50.0

Mid-market price

1,440pΒ 

3.3

17.6

55.7

70.8

41.9

Discount to diluted NAV *

17.7%Β 

Standard & Poor's 500 Composite Index **

1,073.0

7.4

21.3

26.2

43.2

51.9

Russell 2000 **

647.5

7.8

26.1

30.1

42.3

91.9

FTSE All-Share Index

5,090.8

5.0

15.3

30.1

44.1

35.2

US Dollar/Sterling exchange rate

1.5161

0.1

5.4

1.5

(4.4)

23.5

Β 

* Following the conversion of the Loan Stock, the performance is shown on the diluted NAV (excluding retained revenue for the period) only. The Board considers that this accurately reflects the underlying performance of the Company.

** Sterling adjusted.

Β 

Β 

Material Events and Transactions during the Period

Β 

During the period under review, the Company's Convertible Unsecured Loan Stock 2013 ("the Loan Stock") was all either converted voluntarily by the Loan Stockholders themselves, or was then compulsorily converted by the Trustee of the Loan Stock and subsequently sold with the proceeds from that sale then being distributed rateably to Stockholders. Following this, the Company no longer has anyΒ Loan Stock.

Β 

There have been no material transactions during the quarter ended 31 May 2013.

Β 

Transaction in Own Shares

Β 

There have been no transactions in the Company's own shares during the quarter ended 31 May 2013.

Β 

Β 

TEN LARGEST INVESTMENTS AT 31 MAY 2013 Percentage of Portfolio

Gleeson (MJ) Group

UK Listed

11.0

US Treasury Bills

US Treasury Bills

10.5

Oryx International Growth Fund Limited *

UK Listed

9.6

Bionostics Holdings Limited

US Unquoted

8.8

Trident Private Equity Fund III LLP

UK Unquoted

7.8

Hampton Investment Properties Limited

UK Unquoted

5.1

Celsis AG

US Unquoted

4.7

Bioquell

UK Listed

3.4

Guinness Peat Group **

UK Listed

3.4

AssetCo PLC

UK Listed

3.3

% of total portfolio

67.6

Β 

* incorporated in Guernsey

** incorporated in New Zealand

Β 

SECTOR ANALYSIS OF INVESTMENTS AT FAIR VALUE AS AT 31 MAY 2013

Β 

UnitedΒ 

UnitedΒ 

TotalΒ 

StatesΒ 

KingdomΒ 

EuropeΒ 

%Β 

%Β 

%Β 

%Β 

Investment Companies

10.1

9.6

19.7

Health Care, Equipment & Services

0.2

11.1

11.3

Construction & Materials

11.0

11.0

Treasury Bills

10.5

10.5

Manufacturing

8.8

8.8

Real Estate

7.5

0.4

7.9

General Financials

4.3

4.3

Support Services

1.3

2.6

3.9

Financial Services

3.4

3.4

Industrial Engineering

3.3

3.3

General Industrials

1.2

1.5

2.7

General Retailers

2.7

2.7

Transportation

2.6

2.6

Media

0.5

1.8

2.3

Travel & Leisure

2.1

2.1

Oil & Gas Producers

1.1

0.8

1.9

Technology Hardware & Equipment

1.6

1.6

Β 

The financial information for the period ended 31 May 2013 contained within this Interim Management Statement has not been audited.

Β 

By order of the Board

Β 

Β 

Bonita Guntrip

Company Secretary

18 June 2013

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSKMGMVFRLGFZM
Date   Source Headline
6th Aug 20259:57 amRNSTransaction in Own Shares and TVR
15th Jul 20259:34 amRNSNet Asset Value(s)
7th Jul 20251:00 pmRNSTransaction in Own Shares and TVR
7th Jul 202511:34 amRNSTransaction in Own Shares and TVR
19th Jun 20259:51 amRNSTransaction in Own Shares nad TVR
13th Jun 20253:52 pmRNSNet Asset Value(s)
12th Jun 20251:50 pmRNSShare Split and Total Voting Rights
12th Jun 20251:46 pmRNSResult of AGM
9th Jun 202510:45 amRNSTransaction in Own Shares and TVR
2nd Jun 20251:15 pmRNSTransaction in Own Shares and TVR
30th May 202511:01 amRNSTransaction in Own Shares and TVR
27th May 20253:26 pmRNSTransaction in Own Shares and TVR
23rd May 20251:44 pmRNSCompany Secretary Change
16th May 20257:00 amRNSNet Asset Value(s)
15th May 20257:00 amRNSAnnual Financial Report & Notice of AGM
7th May 20257:00 amRNSFinal Results
16th Apr 20257:00 amRNSNet Asset Value(s)
3rd Apr 202510:35 amRNSTransaction in Own Shares and TVR
31st Mar 20259:44 amRNSTransaction in Own Shares and TVR
24th Mar 20259:13 amRNSTransaction in Own Shares and TVR
18th Mar 20253:15 pmRNSNet Asset Value(s)
3rd Mar 20252:17 pmRNSTransaction in Own Shares and TVR
27th Feb 20257:00 amRNSDividend Declaration
17th Feb 202512:49 pmRNSTransaction in Own Shares and TVR
14th Feb 20259:26 amRNSNet Asset Value(s)
10th Feb 202511:05 amRNSTransaction in Own Shares and TVR
15th Jan 202511:10 amRNSDirector Declaration
15th Jan 202511:01 amRNSDirector Declaration
15th Jan 202510:39 amRNSNet Asset Value(s)
12th Dec 20241:48 pmRNSNet Asset Value(s)
29th Nov 202411:57 amRNSTransaction in Own Shares
25th Nov 202410:10 amRNSTransaction in Own Shares
15th Nov 202410:57 amRNSNet Asset Value(s)
11th Nov 202410:30 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSDirector/PDMR Shareholding
28th Oct 202411:50 amRNSNet Asset Value(s)
28th Oct 20247:00 amRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 202411:51 amRNSInvestment Update: Performance Chemicals
3rd Oct 20247:00 amRNSTransaction in Own Shares
26th Sep 20247:00 amRNSHalf-year Report - Replacement
25th Sep 20247:00 amRNSHalf-year Report
13th Sep 20247:00 amRNSNet Asset Value(s)
14th Aug 202410:40 amRNSNet Asset Value(s)
26th Jul 202410:20 amRNSTransaction in Own Shares
25th Jul 202411:08 amRNSTransaction in Own Shares
23rd Jul 20247:00 amRNSTransaction in Own Shares
17th Jul 20243:35 pmRNSTransaction in Own Shares
11th Jul 20247:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.